Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention.

ABSTRACT:

Importance

Therapies for individual keratinocyte carcinomas (KCs) do not prevent the onset of new KCs in a field of sun damage, and therefore the KC burden remains unchanged.

Objective

To investigate the association of immune checkpoint inhibitors (ICIs) with changes in field cancerization evaluated by the number of actinic keratoses (AKs) and KCs at baseline compared with 12 months after starting ICI therapy.

Design, setting, and participants

This prospective cohort study was performed at the outpatient oncology clinic of a single tertiary public hospital in Brisbane, Australia, from April 1, 2022, to November 30, 2023. Consecutive immunocompetent adults starting therapy with an inhibitor for programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PDL-1) fo

SUBMITTER: Cox C 

PROVIDER: S-EPMC11822595 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature